Efficacy and safety of once‐weekly glucagon‐like peptide 1 receptor agonist albiglutide ( HARMONY 1 trial): 52‐week primary endpoint results from a randomized, double‐blind, placebo‐controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin
Year: 2014
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Diabetes Obesity and Metabolism
DOI: 10.1111/dom.12382
Authors: J. Reusch, M. W. Stewart, C. M. Perkins, D. T. Cirkel, J. Ye, C. R. Perry, R. R. Reinhardt, B. W. Bode
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: GlaxoSmithKline
OpenAlex ID: W1945841307
